Diagnosis
Gene finding paves way for new targeted breast cancer treatment

A gene linked to triple negative breast cancer could point to a new targeted treatment, researchers say.
Triple negative breast cancer makes up about 15 per cent of breast cancer cases. This form of the disease can be more aggressive and harder to treat than other types, with fewer targeted treatment options available.
It is also more common in women with an inherited altered BRCA gene, women under 40 and Black women.
The gene, called HORMAD1, is usually active only in reproductive cells in the ovaries and testes and stays switched off in the rest of the body. It helps ensure genetic information is distributed properly in sperm and eggs.
But in some cancers, including 60 per cent of triple negative breast cancers, HORMAD1 becomes active where it should not be. Researchers at the Breast Cancer Now Toby Robins Research Centre at The Institute of Cancer Research, London, and the Breast Cancer Now Research Unit at King’s College London found that this disrupts a key safety mechanism in cells, causing errors in DNA to be passed on to new cancer cells.
While those changes can help cancer grow and resist treatment, the researchers said they also create a weakness that could be targeted with new therapies.
The study identified several drugs already being investigated as cancer treatments that may work against triple negative breast cancer cells with an active HORMAD1 gene. The team tested whether blocking three specific proteins, Aurora B, MPS1 and BUB1, could stop the growth of cells with the active gene in the laboratory.
They also tested whether two Aurora B inhibitors, currently in early-stage clinical trials, could treat mice carrying human triple negative breast cancer tumours with the active HORMAD1 gene. The treatment reduced tumour growth. The researchers said they will now investigate whether drugs targeting Aurora B, MPS1 and BUB1 could be developed for patients with this type of breast and possibly other cancers.
Professor Andrew Tutt, director of the Breast Cancer Now Toby Robins Research Centre at The Institute of Cancer Research, London, and the Breast Cancer Now Research Unit at King’s College London, and corresponding author of the study, said:
“Although this research is still in its early stages, it offers an important step forward in understanding triple negative breast cancer and opens the door for the development of new treatments. It also highlights that testing for the activity of the HORMAD1 gene in triple negative breast cancer could guide treatment decisions in the future. Together, these insights bring us closer to developing more precise therapies for people with triple negative breast cancer.”
Dr Simon Vincent, chief scientific officer at Breast Cancer Now, which funded the research, said:
“Each year, around 8,000 UK women are diagnosed with triple negative breast cancer and it’s more likely than most other breast cancers to return or spread during the first years following treatment. There are also fewer targeted treatments available, so it’s vital we find new and effective ways to tackle this devastating disease. The findings open the door to the next crucial phase of research, where the research team can identify and test the most effective drugs or drug combinations against triple negative breast cancer with an active HORMAD1 gene, and move the safest and most promising options towards clinical trials.”
Liz Boughton, 50, an NHS finance manager from Northamptonshire, was diagnosed with triple negative breast cancer in August 2024. She said:
“In July 2024, I accidentally brushed my arm against my breast and felt a very small lump. I dismissed it until I was persuaded by my husband to make an appointment with my doctor. I was quickly referred to the breast clinic, where a whirlwind of tests led to a diagnosis of triple negative breast cancer. I was 49, healthy, with no family history. Cancer wasn’t something I expected to hear.”
“I began 6 months of neo-adjuvant chemotherapy immediately, to shrink the tumour before surgery. I was also given immunotherapy (weekly) alongside the chemotherapy, a new treatment option for some people with triple negative breast cancer, which can improve outcomes. Once treatment began, it pulled me, and those around me, into a world we never knew existed. I then underwent surgery, followed by radiotherapy and a further 9 infusions of immunotherapy over 27 weeks.”
“When you’re diagnosed with a type of breast cancer that has fewer treatment options and a higher risk of returning soon after diagnosis, it’s hard not to live with constant uncertainty about the future. It can feel like you’ve been given a life sentence, but with continued research comes hope.”
Diagnosis
WHO launches AI tool for reproductive health information

The World Health Organization (WHO) has launched an AI tool in beta to help policymakers, experts and healthcare professionals access sexual and reproductive health information faster.
Called ChatHRP, the tool was created by WHO’s Human Reproduction Programme and draws only on verified research and guidance collected by HRP and WHO.
It uses natural language processing and retrieval-augmented generation to produce referenced content and cut the time spent searching through documents across different platforms and databases.
WHO said ChatHRP also has multilingual capabilities and low-bandwidth functionality to support use in a wide range of settings.
The beta-testing phase is aimed at a broad professional audience, including policymakers, healthcare workers, researchers and civil society groups.
WHO said the tool can help users quickly access up-to-date evidence, find sources for academic work and verify information on sexual and reproductive health and rights.
Examples of questions it can answer include the latest violence against women data in Oceania for women aged 15 to 49, recommendations on managing diabetes during pregnancy, and whether PrEP and contraception can be used at the same time. PrEP is medicine used to reduce the risk of getting HIV.
WHO added that the system will be updated regularly as new HRP materials are published and includes a feedback loop so users can flag gaps in the information provided.
The launch comes amid wider concern about misinformation in sexual and reproductive health.
A 2025 scoping review found that misinformation in digital spaces is a systemic issue that can undermine human rights, reinforce discriminatory social norms and exclude marginalised voices.
The review also said misinformation can affect health systems by shaping provider knowledge and practice, disrupting service delivery and creating barriers to equitable care.
WHO said ChatHRP is intended to give users streamlined access to reliable information as a counter to “algorithms, opinions, or misinformation”.
Diagnosis
AI maps how reproductive organs age differently during menopause
Pregnancy
Early miscarriage care could prevent 10,000 pregnancy losses a year, study finds
Fertility1 week agoFuture Fertility raises Series A financing to scale AI tools redefining fertility care worldwide
Entrepreneur4 weeks agoThree sessions that show exactly where women’s health is heading in 2026
Pregnancy4 weeks agoHow NIPT has evolved and what AI NIPT means in 2026
News4 weeks agoTwo weeks left to make your mark in women’s cardiovascular health
Fertility2 weeks agoFuture Fertility partners with Japan’s leading IVF provider, Kato Ladies Clinic
Menopause2 weeks agoMore research needed to understand link between brain fog and menopause, expert says
Mental health1 week agoLifting weights shows mental health and cognitive benefits in older women, study finds
News3 weeks agoSelf-employment linked to better cardiovascular health outcomes in Hispanic women
















